about
Emerging approaches in Parkinson's disease - adjunctive role of safinamideBenign tremulous Parkinsonism: a unique entity or another facet of Parkinson's disease?Stem cell-based approach for the treatment of Parkinson's diseaseRoles of functional catechol-O-methyltransferase genotypes in Chinese patients with Parkinson's disease.The efficacy and safety of pramipexole ER versus IR in Chinese patients with Parkinson's disease: a randomized, double-blind, double-dummy, parallel-group study.Alexithymia in patients with Parkinson's disease treated with DBS of the subthalamic nucleus: a case-control studyPrevalence of wearing-off and dyskinesia among the patients with Parkinson's disease on levodopa therapy: a multi-center registry survey in mainland ChinaPituitary adenylate cyclase activating polypeptide modulates catecholamine storage and exocytosis in PC12 cells.Age-related neurodegenerative disease research needs aging modelsLow Cerebral Glucose Metabolism: A Potential Predictor for the Severity of Vascular Parkinsonism and Parkinson's Disease.Molecular imaging as a guide for the treatment of central nervous system disordersCurrent status of safinamide for the drug portfolio of Parkinson's disease therapy.Clinical implications of irregular ADMET properties with levodopa and other antiparkinson's drugs.Safinamide for the treatment of Parkinson's disease.Mavoglurant as a treatment for Parkinson's disease.Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease.Pramipexole extended-release: a review of its use in patients with Parkinson's disease.The safety of istradefylline for the treatment of Parkinson's disease.Current and investigational non-dopaminergic agents for management of motor symptoms (including motor complications) in Parkinson's disease.Further explorations of illness uncertainty: carers' experiences of Parkinson's disease.Nondopaminergic therapy of motor and nonmotor symptoms in Parkinson's disease: a clinician's perspective.Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.Loss of Dopamine Transporter Binding and Clinical Symptoms in Dementia With Lewy Bodies.1-[2-(4-Benzyloxyphenoxy)Ethyl]Imidazole inhibits monoamine oxidase B and protects against neuronal loss and behavioral impairment in rodent models of Parkinson's disease.Astaxanthin is neuroprotective in an aged mouse model of Parkinson's disease.Effects of deep brain stimulation on rest tremor progression in early stage Parkinson disease
P2860
Q26740905-50AC43D3-223B-48AA-85F4-96276659857FQ26747010-F778536C-6FD5-40E0-88D9-45B21F1CEBF1Q27004330-C0E41A59-F98A-458D-A8BE-14326CE6905CQ33604514-7CF11430-D19B-4D36-B83C-2B27F0329AC9Q34027252-0523D3D7-71CE-42C3-9809-80EA741FCF37Q34330232-253C080C-EA10-4A99-861F-BE30617D45D9Q35069101-84E178CC-CC36-4F69-90B3-9683512AF0D4Q35113313-4015D24D-5EBF-4B63-902B-5CFCB0A57871Q36018230-E3B220C1-2CAF-4513-9D1E-1A7EDCF86438Q36314846-B8E03FB9-2C9B-4FD0-B989-05B877FF9E9FQ37262953-A1797956-58B8-4EC4-B4A2-134E63B82988Q38140018-4A804854-73CF-487D-A05F-7EE70A13AF26Q38179453-7F960F5A-7F2C-47E4-BD46-FEF8E4ED0B71Q38197710-820214BF-A744-4645-ADCF-9AAE17D71144Q38222814-F1E59059-664A-498E-BB39-F11B9B4C2FA0Q38246682-1C92FCD1-440A-4CD7-B508-EFAA4AED8083Q38266818-D4494E97-184E-4887-A776-C811621A6E22Q38353204-1EB80DA8-DC57-4C76-8AB3-DC640E72CF1FQ38636630-CCAEBCF7-BE21-42AB-972D-ED0E45747891Q38748398-03C691D7-B4BA-483D-BFAF-57448D43453FQ38947507-53388243-D7E9-4289-BE0E-A30144482900Q39325939-0E6A5D79-02F2-4A45-840A-29977F5D72C4Q48077546-96E9C464-B524-4D1C-B97C-C524BA5BCD1DQ48108548-97F42AC3-1277-4FD6-98D9-D10DB5A4146AQ51763351-E235ECFD-1AC6-4F20-9B4F-DA98AFD5DD28Q57174015-BBB003F2-B8FC-4F7F-BB1C-8C7B61320EDC
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Drug therapy in patients with Parkinson's disease.
@en
type
label
Drug therapy in patients with Parkinson's disease.
@en
prefLabel
Drug therapy in patients with Parkinson's disease.
@en
P2860
P356
P1476
Drug therapy in patients with Parkinson's disease.
@en
P2860
P2888
P356
10.1186/2047-9158-1-10
P577
2012-05-24T00:00:00Z
P5875
P6179
1028401093